Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HEAGN
ADC Name
DB-1202
Synonyms
DB 1202; DB-1202; DB1202
   Click to Show/Hide
Organization
Duality Biologics
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Undisclosed
Payload Name
Undisclosed
Linker Name
Undisclosed
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05785728
Phase 1/2
Phase 1/2, multicenter, open-label, first-in-human study of DB-1202 monotherapy in patients with advanced solid malignant tumors to evaluate the tolerability, safety, pharmacokinetics and antitumor activity.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05785728  Clinical Status Phase 1/2
Clinical Description Phase 1/2, multicenter, open-label, first-in-human study of DB-1202 monotherapy in patients with advanced solid malignant tumors to evaluate the tolerability, safety, pharmacokinetics and antitumor activity.
References
Ref 1 Phase 1/2, Multicenter, Open-label, First-in-human Study of DB-1202 Monotherapy in Patients With Advanced Solid Malignant Tumors to Evaluate the Tolerability, Safety, Pharmacokinetics and Antitumor Activity, NCT05785728